VERO Biotech Raises $100 M led by MVM Partners
- Funding

VERO Biotech Raises $100 M led by MVM Partners

VERO Biotech Receives Funding from MVM Partners to Accelerate Growth

Investment from MVM Partners to support the growth of VERO Biotech’s GENOSYL® Delivery System, a proprietary tankless system for inhaled administration of nitric oxide gas.

ATLANTADec. 21, 2021 /PRNewswire/ — VERO Biotech Inc., a fast-growing commercial business dedicated to improving the lives of patients through innovative technologies, today announced the funding of up to $100 million in a Series E financing round led by MVM Partners (MVM), which included participation from a strategic investor. Funds from the round will support the expanded commercialization of the GENOSYL® Delivery System (GENOSYL® DS).

GENOSYL® DS is the first tankless inhaled nitric oxide (NO) delivery system approved by the U.S. Food and Drug Administration (FDA). NO dilates blood vessels to treat severe pulmonary hypertension, a life-threatening condition that can occur in neonates and patients with respiratory distress. Unlike tank-based systems, GENOSYL® DS generates NO using a small disposable cassette at the bedside. This eliminates the need for hospitals to manage bulky tanks and helps to simplify clinical workflow.

“As MVM is committed to supporting the growth of companies with innovative technologies to treat unmet medical needs, it was clear MVM is the right fit for our next stage of growth,” said Brent V. Furse, CEO, and President, VERO Biotech. “MVM has a deep understanding of our business, and we will be able to leverage MVM’s experience in bringing innovative products to market, driving growth, making strategic acquisitions, and establishing new standards of care in medicine. In addition, VERO’s partnership with MVM will ensure greater access to our proprietary tankless, cassette-based GENOSYL Delivery System.”

Eric Bednarski, Partner of MVM, commented: “VERO Biotech has a best-in-class technology that improves the clinical care of patients requiring inhaled nitric oxide therapy. GENOSYL has gained significant market traction with adoption by some of the top hospitals in the U.S. We are extremely impressed by the management team and excited to partner with VERO Biotech to help the company achieve its near- and long-term goals.”


See also  Paceline Raises $29.5 Million Transform Traditional Financial Services Models


GENOSYL (nitric oxide) gas, for inhalation, is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

Important Safety Information

  • GENOSYL is contraindicated in treating neonates dependent on right-to-left shunting of blood.
  • Abrupt discontinuation of GENOSYL (nitric oxide) gas for inhalation may worsen oxygenation and increase pulmonary artery pressure.
  • Methemoglobin levels in the blood increase with the dose of nitric oxide; following discontinuation or reduction of nitric oxide, methemoglobin levels return to baseline over hours.
  • Methemoglobin, NO2, and PaO2 should be monitored during nitric oxide administration.
  • In patients with pre-existing left ventricular dysfunction, GENOSYL may increase pulmonary capillary wedge pressure leading to pulmonary edema.
  • The most common adverse reaction is hypotension.
  • Nitric oxide donor compounds may have an additive effect with GENOSYL on the risk of developing methemoglobinemia.
  • GENOSYL must be administered using a calibrated GENOSYL Delivery System. Only validated ventilator systems or nasal cannulas should be used with GENOSYL.

Please visit for the full Prescribing Information for GENOSYL.


GENOSYL DS is VERO Biotech’s lead product. This proprietary delivery system eliminates the need for large nitric oxide tanks and the associated logistical burden.  GENOSYL DS is a tankless and portable system engineered with redundant backup features, which delivers a constant concentration of inhaled nitric oxide gas to patients with an easy-to-use interface and portability features.

About VERO Biotech

See also  Healthy.Capital Invests in Nori Health to fight Chronic Bowel Disease

VERO Biotech Inc. (formerly known as GeNO LLC) focuses on the design, development, and commercialization of next-generation products to address the unmet medical needs of patients with various pulmonary and cardiac diseases.

VERO Biotech is dedicated to improving patients’ lives by leading the development of innovative technologies for inhaled nitric oxide delivery in the acute care hospital setting and beyond, wherever inhaled nitric oxide treatment is needed.

About MVM Partners

MVM has invested in innovative, high-growth healthcare businesses since 1997. With teams in Boston and London, MVM has a successful track record of investing across most healthcare sub-sectors, including medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, and digital health. In aggregate, MVM has raised investment vehicles totaling over $1 billion.

Forward-Looking Statements

This press release and any statements of representatives of VERO Biotech Inc. related thereto that are not historical contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, without limitation, statements concerning VERO Biotech’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “seeks,” “intends,” “plans,” “potential” or similar expressions, including statements concerning the potential effects of its products and plans to assess and undertake next steps for VERO Biotech Inc.  These statements are based upon the current beliefs and expectations of VERO Biotech’s management and are subject to significant risks and uncertainties. Actual results may differ significantly from those outlined in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various risk factors (many of which are beyond VERO Biotech’s control).

See also  New Solutions, Investments, And M&A to Raise Adoption of Digital Health

For information, please visit or contact Ray Russo at [email protected] or (908) 313-7172.

VERO Biotech Raises $100 M led by MVM Partners